A 10-year event-free survival gap of 77% versus 32% between MRD-negative and MRD-positive pediatric ALL patients is exactly the kind of statistic that reframes a diagnostic authorization as something far more consequential than regulatory paperwork. Imviva Biotech has received FDA clearance of its Investigational Device Exemption for Adaptive Biotechnologies’ clonoSEQ assay in TENACITY-01, the Phase 1b/2 trial evaluating CTD402, its allogeneic anti-CD7 CAR-T therapy, in relapsed/refractory T-ALL/LBL and MRD-positive patients in remission. The IDE authorization is what allows clonoSEQ to operate inside a regulated clinical program where its results directly drive patient management decisions, a higher bar than routine laboratory use.
The assay carries two distinct functions inside TENACITY-01, and that dual role is where the design gets interesting. At the front end, patients must have MRD levels at or above 0.1% to qualify for enrollment in the MRD-positive cohort, making clonoSEQ a gating mechanism rather than a passive biomarker. At the back end, post-treatment bone marrow samples get assessed to track depth of response and support exploratory analyses of CTD402’s durability. That structure positions MRD not just as an eligibility filter but as the primary lens through which CTD402’s allogeneic platform will be judged. Per ClinicalTrials.gov, the trial plans roughly 18 participants in Phase 1b dose exploration, 18 more at the recommended Phase 2 dose, then approximately 36 in the expansion phase, a staged build that keeps early read-outs tight before broader enrollment commits.
CTD402 itself carries meaningful regulatory tailwinds: FDA has granted it both Rare Pediatric Disease Designation and Regenerative Medicine Advanced Therapy designation for relapsed/refractory T-ALL. The RMAT designation in particular allows for more frequent FDA interactions and, if efficacy data hold, an expedited review pathway. The allogeneic construct uses TCR and HLA class II knockout plus Imviva’s proprietary ANSWER inhibitory ligands to resist host immune rejection, which is the central engineering challenge in off-the-shelf CAR-T. Eliminating manufacturing lead time matters acutely in a disease where delay is itself a clinical risk. Patients with rapidly progressive T-ALL simply may not survive an autologous manufacturing cycle.
The clinical signal to track closely is how MRD clearance rates in the MRD-positive cohort compare across the Phase 1b and expansion stages. If CTD402 drives patients below the 0.01% threshold that NCCN recognizes as a clinically actionable cutoff, that will shape the regulatory conversation about the depth of response needed to support an accelerated approval filing in this indication.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
